PatentsUSA
Supreme Court Agrees to Review Amarin’s 'Skinny Label' Patent Dispute
The US Supreme Court has granted certiorari to hear a patent infringement case centered on the 'skinny label' strategy employed by generic drug manufacturers, involving Amarin Pharma. The case will address whether a generic drug maker can be held liable for inducing infringement when its product is labeled for non-pat…
Thursday, May 14, 2026